Bivalirudin Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Study-level Meta-analysis of Randomized Controlled Trials
Meta-analysis published in Cardiovascular Drugs and Therapy (2024)
Abstract
AIMS: The present meta-analysis focused on investigating whether bivalirudin plus post-PCI infusion was safer and more effective than heparin monotherapy in patients who developed ST-segment elevation myocardial infarction (STEMI) and who underwent primary percutaneous coronary intervention (PCI). METHODS: The PubMed, EMBASE, Cochrane Library, and Web of Science databases were systemically searched to identify randomized controlled trials (RCTs) comparing bivalirudin and heparin for treating STEMI patients who underwent primary PCI. The Cochrane quality assessment tool was used to assess the quality of the enrolled studies. The primary and secondary outcomes included net adverse clinical events (NACEs, comprising all-cause death or major bleeding), major adverse cardiovascular events (MACEs, comprising all-cause death, stroke, MI, and TVR), in-stent thrombosis (IST), and bleeding of Bleeding Academic Research Consortium (BARC) types 2, 3, and 5. RESULTS: The four RCTs, comprising 10,695 events, included 5350 patients who received bivalirudin combined with post-PCI infusion and 5345 patients who received heparin monotherapy. Compared with those in the heparin group, the number of NACEs (RR 0.84, 95% CI 0.73-0.96, P = 0.009), MACEs (RR 0.82, 95% CI 0.67-0.99, P = 0.04), and ISTs (RR 0.66, 95% CI 0.49-0.91, P < 0.0001) in the bivalirudin group was significantly lower. There were no significant differences in all-cause death, cardiac death, stroke, MI, TVR, or BARC type 2, 3, or 5 bleeding between the two groups. CONCLUSION: In STEMI patients undergoing primary PCI, bivalirudin plus post-PCI infusion significantly reduced the incidence of NACEs, MACEs, and ISTs compared with heparin monotherapy, without increasing the risk of MI or TVR. Bivalirudin may also contribute to a potential reduction in stroke, death, and BARC type 2, 3, and 5 bleeding rates.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
Meta-analysis of four randomized trials (10,695 STEMI patients) found bivalirudin plus post-PCI infusion lowered net adverse clinical events, major adverse cardiovascular events and in-stent thrombosis versus heparin monotherapy, with no significant bleeding difference.
Why This Matters for Hirudotherapy
This meta-analysis of four randomized controlled trials (n=10,695 STEMI patients undergoing primary PCI) compared bivalirudin plus post-PCI infusion against heparin monotherapy on net adverse clinical events, major adverse cardiovascular events, and in-stent thrombosis. Bivalirudin was associated with significantly lower rates of NACEs, MACEs, and ISTs, with no significant differences in individual components such as all-cause death, stroke, or BARC type 2/3/5 bleeding. Bivalirudin is a hirudin-based direct thrombin inhibitor. However, this work concerns a synthetic pharmaceutical analog studied in interventional cardiology.
Citation
Reference (Vancouver style)
Sun B, Chen RR. Bivalirudin Versus Heparin Monotherapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Study-level Meta-analysis of Randomized Controlled Trials. Cardiovasc Drugs Ther. 2025;39(5):1075-1084. doi:10.1007/s10557-024-07609-6. PMID: 39080125
Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.
Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026